A new study in the journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick disease, type C1 ...

A new study in the peer-reviewed journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick ...

A new study in the peer-reviewed journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick disease, type C1 (NPC1) who were tested lacked neutralizing antibodies against ...

A new study in the peer-reviewed journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick disease, type C1 (NPC1) who ...

LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to ...